Skip to main content
SpringerLink
Log in

Azacytidine for the treatment of myelodysplastic syndromes in the elderly

  • Clinical Cases
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The management of myelodysplastic syndromes (MDS) in elderly patients is a significant clinical problem. The therapeutic options range from observation alone for patients with low-risk disease, lenalidomide for patients with 5q-syndrome, to 5-azacytidine (5-AZA) for patients with higher risk of disease. In this paper, we summarize the clinical course of three patients with high-risk MDS treated with 5-AZA as well as the management and supportive care measures for adverse events. As expected, based on available clinical trials data, the agent resulted in clinical and hematological improvement in these patients with acceptable side effects. 5-AZA is an attractive option for elderly patients with high-risk MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lee JS, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801–808.

    Article  PubMed  CAS  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.

    PubMed  CAS  Google Scholar 

  3. The International Agency for Research on Cancer. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th Edition. Lyon: IARC Press; 2008.

  4. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.

    PubMed  CAS  Google Scholar 

  5. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510.

    Article  PubMed  Google Scholar 

  6. Park MJ, Kim HJ, Kim SH, et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol. 2008;81:364–373.

    PubMed  Google Scholar 

  7. Hasse D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87:515–526.

    Article  Google Scholar 

  8. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.

    Article  PubMed  CAS  Google Scholar 

  9. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004.

    PubMed  CAS  Google Scholar 

  10. Aul C, Gatterman N, Schneider W. Age related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358–367.

    Article  PubMed  CAS  Google Scholar 

  11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukaemia group B. J Clin Oncol. 2002;20:2429–2440.

    Article  PubMed  CAS  Google Scholar 

  12. Kantarijan H, O’Brien S, Ravandi F. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.

    Article  Google Scholar 

  13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.

    Article  PubMed  CAS  Google Scholar 

  14. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.

    Article  PubMed  CAS  Google Scholar 

  15. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol. 2010;76:218–227.

    Article  Google Scholar 

  16. Santini V, Fenaux P, Mufti GJ. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacytidine. Eur J Haematol. 2010;85:130–138.

    PubMed  CAS  Google Scholar 

  17. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Universitario, Salamanca, Spain

    Maria Diez Campelo

  2. Department of Hematology, Hospital Virgen de la Victoria, Malaga, Spain

    Regina Garcia Delgado

  3. Department of Hematology and Hemotherapy, Hospital Universitario Miguel Servet, Zaragoza, Spain

    Ana Cristina Godoy Molias

  4. Department of Hematology and Hemotherapy, Hospital San Pedro, Logroño, Spain

    Jesus Feliu Sanchez

Authors
  1. Maria Diez Campelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Regina Garcia Delgado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Cristina Godoy Molias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jesus Feliu Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jesus Feliu Sanchez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campelo, M.D., Delgado, R.G., Molias, A.C.G. et al. Azacytidine for the treatment of myelodysplastic syndromes in the elderly. Adv Therapy 28 (Suppl 2), 10–15 (2011). https://doi.org/10.1007/s12325-010-0097-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0097-3

Keywords

Search

Navigation